APA (7th ed.) Citation

Jones, N. S., Kshirsagar, S., Mohanan, V., Ramakrishnan, V., Di Nucci, F., Ma, L., . . . Rothenberg, M. E. (2023). A phase I, randomized, ascending‐dose study to assess safety, pharmacokinetics, and activity of GDC‐8264, a RIP1 inhibitor, in healthy volunteers. Clinical and translational science, 16(10), 1997-2009. https://doi.org/10.1111/cts.13607

Chicago Style (17th ed.) Citation

Jones, Nicholas S., et al. "A Phase I, Randomized, Ascending‐dose Study to Assess Safety, Pharmacokinetics, and Activity of GDC‐8264, a RIP1 Inhibitor, in Healthy Volunteers." Clinical and Translational Science 16, no. 10 (2023): 1997-2009. https://doi.org/10.1111/cts.13607.

MLA (9th ed.) Citation

Jones, Nicholas S., et al. "A Phase I, Randomized, Ascending‐dose Study to Assess Safety, Pharmacokinetics, and Activity of GDC‐8264, a RIP1 Inhibitor, in Healthy Volunteers." Clinical and Translational Science, vol. 16, no. 10, 2023, pp. 1997-2009, https://doi.org/10.1111/cts.13607.